---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-004977"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2026-07-29T11:20:33+00:00"
generated_at: "2026-07-29T11:25:10.098506+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Anika Q2 revenue $32.6M (+16% YoY); raises FY 2026 guidance, adj. EBITDA margin 13-17%

## Summary
- Q2 revenue $32.6M, up 16% YoY; Commercial Channel record $13.9M (+17%); OEM $18.7M (+14%).
- Gross margin 65%; net income $3.3M ($0.24 diluted EPS); adjusted EBITDA $7.1M (22% margin).
- Raising FY 2026 guidance: total revenue growth 5-10% (prev 1-9%); adj. EBITDA margin 13-17% (prev 5-10%).
- Revised 2027 Commercial revenue growth 5-15% (prev 10-20%); total company flat to 5% growth.
- International revenue record $12.6M (+22% YoY); Integrity units up 39% YTD; Hyalofast/Cingal progress.

## SEC filing metadata
- accession: 0001171843-26-004977
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2026-07-29T11:20:33+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184326004977/0001171843-26-004977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184326004977/f8k_072926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-004977
- JSON: https://secwatch.observer/filing/0001171843-26-004977.json
- Plain text: https://secwatch.observer/filing/0001171843-26-004977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.